Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years : Committee papers
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.